Improve Warfarin Therapy or Use Dabigatran for Patients with Atrial Fibrillation - A Cost-Effectiveness Analysis

被引：0
|
作者：
You, Joyce H. [1 ]
Tsui, Kia K. [1 ]
Wong, Raymond S.
Cheng, Gregory
机构：
[1] Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1334 / 1334
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
    Davidson, Thomas
    Husberg, Magnus
    Janzon, Magnus
    Oldgren, Jonas
    Levin, Lars-Ake
    EUROPEAN HEART JOURNAL, 2013, 34 (03) : 177 - 183
  • [2] Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
    Wei, Hongtao
    Cui, Can
    Cui, Xiangli
    Liu, Yi
    Li, Dandan
    BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [3] COST-EFFECTIVENESS OF DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION MANAGEMENT IN COLOMBIA
    Alfonso-Cristancho, R.
    Herran, S.
    Caicedo, M.
    Gomez, E.
    VALUE IN HEALTH, 2011, 14 (07) : A536 - A537
  • [4] Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
    Freeman, James V.
    Zhu, Ruo P.
    Owens, Douglas K.
    Garber, Alan M.
    Hutton, David W.
    Go, Alan S.
    Wang, Paul J.
    Turakhia, Mintu P.
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) : 1 - U129
  • [5] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Wang, Ye
    Xie, Feng
    Kong, Ming Chai
    Lee, Lai Heng
    Ng, Heng Joo
    Ko, Yu
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (06) : 575 - 585
  • [6] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Ye Wang
    Feng Xie
    Ming Chai Kong
    Lai Heng Lee
    Heng Joo Ng
    Yu Ko
    Cardiovascular Drugs and Therapy, 2014, 28 : 575 - 585
  • [7] ANALYSIS OF COST-EFFECTIVENESS OF WARFARIN VS. DABIGATRAN ETEXILATE IN ATRIAL FIBRILLATION IN ECUADOR
    Penaherrera, E.
    Tettamanti, D.
    Aguirre, F.
    Puyol, L. F.
    Cardenas, E.
    Torres, G.
    Herran, S.
    VALUE IN HEALTH, 2015, 18 (07) : A830 - A830
  • [8] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    STROKE, 2013, 44 (06) : 1676 - +
  • [9] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [10] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
12345